Study summary

BTK inhibitors shrank CNS lymphoma in about three-quarters of patients

BTK inhibitor meta-analysis · 935 people, 40 studies · Published September 2025, Cancer

73%pooled response rate

What was tested

A pooled analysis of 40 studies of BTK inhibitors (ibrutinib, zanubrutinib, orelabrutinib and others), alone or with chemotherapy, for primary and secondary CNS lymphoma.

What they found

What it means

Supports adding BTK inhibitors to first-line chemotherapy, now being tested in randomized trials.

Cancer, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.